# Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg

> **NCT00649558** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pioglitazone HCl Tablets 45 mg
- **DRUG:** Actos® Tablets 45 mg

## Key facts

- **NCT ID:** NCT00649558
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649558, "Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00649558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*